For people diagnosed with gout, understanding your medication options is one of the most important steps in managing this condition. Two of the most commonly prescribed urate-lowering therapies (ULT) are allopurinol and febuxostat. Both medications work by reducing uric acid production in the body, but they have different characteristics, benefits, and considerations.
This guide breaks down everything you need to know about these two medications to have an informed conversation with your healthcare provider.
Understanding How These Medications Work
Both allopurinol and febuxostat belong to a class of drugs called xanthine oxidase inhibitors (XOIs). They work by blocking an enzyme called xanthine oxidase, which is responsible for converting purines into uric acid. By inhibiting this process, both medications help lower the amount of uric acid circulating in your blood, which can reduce the risk of painful gout flares and prevent complications like tophi and kidney damage.
However, they differ in their potency, dosing, and how they are metabolized by the body.
Allopurinol: The First-Line Standard
Allopurinol has been the gold standard for urate-lowering therapy for decades. It is typically recommended as the first-line treatment by the American College of Rheumatology (ACR) guidelines due to its well-established safety profile and cost-effectiveness.
How Allopurinol Works
Allopurinol is a structural analog of hypoxanthine, a natural purine. It inhibits both the active and inactive forms of xanthine oxidase. Once absorbed, it is converted to oxypurinol, which is the active metabolite responsible for the drug’s urate-lowering effects.
Dosing and Titration
One of the key aspects of allopurinol therapy is proper dose titration. Starting with a low dose (typically 100 mg daily) and gradually increasing every 2-4 weeks helps minimize the risk of triggering a gout flare during the initiation phase. The maximum approved dose is 800 mg daily, but most patients achieve target uric acid levels at doses between 200-300 mg daily.
For patients with chronic kidney disease (CKD), dosing requires special attention. The starting dose should be no more than 100 mg daily (or even 50 mg for those with severe CKD), with careful monitoring and slower titration.
Side Effects and Considerations
The most common side effects include skin rash, which can occasionally be severe (Stevens-Johnson syndrome in rare cases), and gastrointestinal symptoms like nausea. Allopurinol requires dose adjustment in patients with renal impairment.
A small percentage of patients carry the HLA-B*5801 allele, which is associated with an increased risk of severe cutaneous adverse reactions. This allele is more common in certain ethnic populations, including those of Han Chinese, Thai, and Korean descent.
Febuxostat: A More Potent Alternative
Febuxostat (brand name Uloric) was approved by the FDA in 2009 as an alternative to allopurinol. It offers greater potency in reducing serum uric acid levels.
How Febuxostat Works
Febuxostat is a non-purine selective xanthine oxidase inhibitor. Unlike allopurinol, it does not require metabolic conversion to an active metabolite. It selectively inhibits both the reduced and oxidized forms of xanthine oxidase.
Dosing and Administration
Febuxostat is available in fixed doses of 40 mg and 80 mg daily, offering more predictable dosing compared to allopurinol. The 40 mg starting dose may be sufficient for many patients, but the 80 mg dose is available for those who need stronger urate lowering. No dose adjustment is required for patients with mild to moderate renal impairment.
Cardiovascular Considerations
A major consideration with febuxostat is its potential cardiovascular risk. The CARES trial (2018) found a comparable risk of cardiovascular death with febuxostat versus allopurinol, though some studies have suggested a possible increased risk of cardiac events with febuxostat in certain high-risk patients. The FDA has issued a warning about this potential risk, and patients with a history of cardiovascular disease should discuss this with their healthcare provider.
Side Effects
Common side effects include liver function abnormalities, nausea, joint pain, and rash. Most side effects are mild and resolve with continued use.
Comparing Effectiveness: What Does the Research Say?
Recent meta-analyses have provided valuable insights into the comparative effectiveness of these two medications.
According to a network meta-analysis published in 2025, febuxostat at 120 mg demonstrated greater reduction in serum uric acid levels compared to allopurinol and benzbromarone. However, allopurinol at 200-300 mg was found to be the best choice for reducing gout flares.
Another meta-analysis (2025) found that febuxostat significantly increased the number of patients achieving target serum uric acid levels of 6.0 mg/dL or less, particularly at doses above 80 mg daily. The study concluded that febuxostat has a favorable safety profile, though more high-quality studies are needed.
Key Differences at a Glance
| Characteristic | Allopurinol | Febuxostat |
|---|---|---|
| First-line recommendation | Yes, preferred | Second-line option |
| Starting dose flexibility | Requires titration | Fixed 40 mg or 80 mg |
| Renal dose adjustment | Required | Not required |
| Cardiovascular warnings | No specific warnings | FDA black box warning |
| Cost | Generally lower | Generally higher |
| Maximum dose | 800 mg daily | 120 mg daily |
Making the Right Choice for You
The choice between allopurinol and febuxostat depends on several individual factors:
Consider allopurinol if:
– You have mild to moderate gout
– Cost is a significant consideration
– You have normal kidney function or are willing to have doses carefully adjusted
– You want the most established safety profile
Consider febuxostat if:
– You have not achieved target uric acid levels with allopurinol despite adequate dosing
– You have chronic kidney disease (stages 3-4)
– You need more potent urate lowering
– You have not tolerated allopurinol
Starting Either Medication: What to Expect
Regardless of which medication you and your doctor choose, starting urate-lowering therapy requires patience. During the first few months, you may actually experience more gout flares as uric acid crystals dissolve in your joints. This is normal and does not mean the medication is not working.
Your doctor may recommend:
– Starting with a low dose and increasing gradually
– Taking colchicine or an NSAID prophylactically during the first 3-6 months
– Staying well hydrated
– Avoiding known dietary triggers
Regular blood tests to monitor your uric acid levels will help determine if your dose needs adjustment.
The Bottom Line
Both allopurinol and febuxostat are effective urate-lowering medications that can help you achieve the ACR-recommended target serum uric acid level of less than 6.0 mg/dL (or below 5.0 mg/dL in patients with tophi).
Allopurinol remains the recommended first-line option due to its established safety profile and lower cost. Febuxostat is a valuable alternative for patients who do not respond adequately to allopurinol or who have specific contraindications.
The most important step is to work closely with your healthcare provider, have realistic expectations about the treatment timeline, and commit to long-term medication adherence. With proper treatment, most people with gout can achieve significant improvement in their symptoms and quality of life.
Frequently Asked Questions
Q: Can I switch from allopurinol to febuxostat if one is not working?
A: Yes. If you have not achieved target uric acid levels with an adequate dose of allopurinol (typically 300-400 mg daily), or if you experience intolerable side effects, your doctor may consider switching you to febuxostat.
Q: Do I need to take these medications forever?
A: For most people with gout, urate-lowering therapy is a long-term commitment. Stopping medication typically leads to a rise in uric acid levels and return of symptoms. Your doctor will monitor your progress and may consider dose reduction only after you have maintained target uric acid levels for an extended period with no flares.
Q: Can I take either medication during a gout flare?
A: It is generally recommended to continue your urate-lowering medication during a flare unless your doctor advises otherwise. Stopping and starting medication can cause fluctuations in uric acid levels that may worsen flares.
Q: Are there any food restrictions when taking these medications?
A: Unlike earlier concerns, there are no specific dietary restrictions mandated by either medication. However, maintaining a balanced diet and limiting high-purine foods can complement your medication therapy.
References
- American College of Rheumatology. 2020 Guideline for the Management of Gout. Arthritis and Rheumatology. 2020.
- Zhang X, et al. Efficacy and safety of different doses of febuxostat and allopurinol: A meta-analysis. Joint Diseases and Related Surgery. 2024.
- Wang Y, et al. Efficacy of different dosages of common uric acid-lowering medications in gout patients: a network meta-analysis. Frontiers in Pharmacology. 2025.
- Food and Drug Administration. FDA Adds Boxed Warning to Febuxostat. 2019.
- Juraschek SP, et al. Effects of the DASH Diet and Sodium Intake on Serum Uric Acid. Arthritis Rheumatol. 2017.